PharmacovigilanceOfficial

FTC sues to block Covetrus's $3.5bn acquisition of veterinary distributor MWI

🇺🇸 FTC · Fri 13 Nov 2026

The US antitrust agency says combining the two largest distributors to veterinary clinics would raise prices and erode service quality across animal health supply.

The US Federal Trade Commission (FTC) has filed suit to stop Covetrus from acquiring rival MWI Veterinary Supply in a deal valued at $3.5 billion. MWI is being sold by Cencora.

According to the agency, the transaction would combine the two largest distributors serving US veterinary clinics. These companies supply veterinary pharmaceuticals, vaccines and clinic consumables.

The FTC alleges that removing competition between the two would lead to higher prices and lower service quality for clinics that depend on these distribution channels.

The case is an antitrust action concerned with competition in veterinary distribution. It carries no direct pharmacovigilance or product-safety implications. Its relevance to regulatory professionals is confined to supply-chain and pricing dynamics for veterinary medicines.

The material available to VigiEye did not include further detail on the litigation, such as the forum, timetable or the parties' response.

What it means for your team

  • Animal health companies should note that the FTC is scrutinising consolidation among distributors of veterinary medicines and vaccines, not only among manufacturers.
  • Market-access and supply-chain teams may wish to monitor the case for potential effects on distributor terms, pricing and service levels in the US veterinary channel.
  • There is no direct pharmacovigilance or product-quality impact; the action concerns competition, not safety.

Official source: FTC ↗

Article written by VigiEye from the official source (FTC). AI-assisted; check the source before acting.

More Pharmacovigilance All →